SEARCH

SEARCH BY CITATION

References

  • 1
    van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. Semin Hematol 1997; 34: 188204.
  • 2
    Harper PL, Luddington RJ, Daly M, Bruce D, Williamson D, Edgar PF, Perry DJ, Carrell RW. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol 1991; 77: 3604.
  • 3
    Lu D, Bovill EG, Long GL. Molecular mechanism for familial protein C deficiency and thrombosis in protein C Vermont (Glu20 [RIGHTWARDS ARROW] Ala and Val34 [RIGHTWARDS ARROW] Met). J Biol Chem 1994; 269: 290328.
  • 4
    Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 58495.
  • 5
    Patel RK, Ford E, Thumpston J, Arya R. Risk factors for venous thrombosis in the black population. Thromb Haemost 2003; 90: 8358.
  • 6
    Bhattacharyya M, Kannan M, Chaudhry VP, Saxena R. Venous thrombosis: prevalence of prothrombotic defects in north Indian population. Indian J Pathol Microbiol 2003; 46: 6214.
  • 7
    Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 103741.
  • 8
    Nicolaes GA, Dahlbäck B. Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states. vi. Hematol Oncol Clin North Am 2003; 17: 3761, vi.
  • 9
    Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJ, Reitsma PH. The 20210 G [RIGHTWARDS ARROW] A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 1999; 104: 504.
  • 10
    Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie YG. Combined carrier status of prothrombin 20210A and factor XIII-A L34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood 2003; 101: 303741.
  • 11
    Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 1525.
  • 12
    van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 367882.
  • 13
    Lavigne G, Mercier E, Quere I, Dauzat M, Gris JC. Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. J Thromb Haemost 2003; 1: 21349.
  • 14
    Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, Manigrasso MR, Basili S, Davi G. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 2003; 88: 53216.
  • 15
    Rauramaa R, Vaisanen SB. Physical activity in the prevention and treatment of a thrombogenic profile in the obese: current evidence and research issues. Med Sci Sports Exerc 1999; 31: S6314.
  • 16
    Rosendaal FR, van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1: 137180.
  • 17
    Rosing J, Tans G. Effects of oral contraceptives on hemostasis and thrombosis. Am J Obstet Gynecol 1999; 180: S37582.
  • 18
    Haapanen-Niemi N, Vuori I, Pasanen M. Public health burden of coronary heart disease risk factors among middle-aged and elderly men. Prev Med 1999; 28: 3438.
  • 19
    Catena C, Novello M, Dotto L, De Marchi S, Sechi LA. Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage. J Hypertens 2003; 21: 2818.
  • 20
    Thorneycroft IH, Goldzieher JW. Venous thromboembolism. A review. J Reprod Med 2003; 48: 91120.
  • 21
    Mann KG, Butenas S, Brummel KE. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23: 1725.
  • 22
    Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 18.
  • 23
    Butenas S, van't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272: 2152733.
  • 24
    Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 14852.
  • 25
    Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: phenotypic quantitation. J Thromb Haemost 2004; 2: 2818.
  • 26
    Mann KG, Brummel-Ziedins K, Undas A, Butenas S. Does the genotype predict the phenotype? Evaluations of the hemostatic proteome. J Thromb Haemost 2004; 2: 172734.
  • 27
    Brummel-Ziedins K, Vossen CY, Rosendaal F, Umezaki K, Mann KG. The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost 2005; 3: 147281.
  • 28
    Cawthern KM, van ’t Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 458192.
  • 29
    Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation 2001; 104: 23117.
  • 30
    Butenas S, Cawthern KM, van't Veer C, DiLorenzo ME, Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001; 97: 231422.
  • 31
    Brummel-Ziedins K, Rivard GE, Pouliot RL, Butenas S, Gissel M, Parhami-Seren B, Mann KG. Factor VIIa replacement therapy in factor VII deficiency. J Thromb Haemost 2004; 2: 173544.
  • 32
    Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 343245.
  • 33
    Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 61724.
  • 34
    Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 2338.
  • 35
    van der Meer FJ, Koster T, Vandenbroucke JP, Briët E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 6315.
  • 36
    Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 1832233.
  • 37
    Lawson JH, Krishnaswamy S, Butenas S, Mann KG. Extrinsic pathway proteolytic activity. Methods Enzymol 1993; 222: 17795.
  • 38
    Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson RD. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16: 280610.
  • 39
    Bajaj SP, Rapaport SI, Prodanos C. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 1981; 11: 397412.
  • 40
    van ’t Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II. J Biol Chem 1997; 272: 436777.
  • 41
    de Visser MC, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 2001; 85: 10117.
  • 42
    Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM. Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 2000; 20: 13826.
  • 43
    Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms – the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 71922.
  • 44
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698703.
  • 45
    Dahm A, van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 438792.
  • 46
    Brummel-Ziedins K, Orfeo T, Jenny NS, Everse SJ, Mann KG. Blood coagulation and fibrinolysis. In: LeeGR, ForesterJ, LukensJ, ParaskevasF, GreerJP, RodgersGM, eds. Wintrobe's Clinical Hematology, 11th edn. Philadelphia: Lippincott Williams & Wilkins, 2003.
  • 47
    Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. A mathematical simulation [published erratum appears in J Biol Chem 1995 Apr 14;270(15):9026]. J Biol Chem 1994; 269: 2336773.
  • 48
    Adams TE, Everse SJ, Mann KG. Predicting the pharmacology of thrombin inhibitors. J Thromb Haemost 2003; 1: 10247.
  • 49
    Butenas S, Orfeo T, Gissel MT, Brummel KE, Mann KG. The significance of circulating factor IXa in blood. J Biol Chem 2004; 279: 2287582.
  • 50
    Orfeo T, Brufatto N, Nesheim ME, Xu H, Butenas S, Mann KG. The factor V activation paradox. J Biol Chem 2004; 279: 1958091.
  • 51
    Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 2335766.
  • 52
    Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 92330.
  • 53
    Tanis BC, Rosendaal FR. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors. Semin Vasc Med 2003; 3: 6984.
  • 54
    Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 152735.
  • 55
    Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Koster T, Bertina RM, Vandenbroucke JP. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost 1998; 80: 3827.
  • 56
    Hemker HC, Al Dieri R, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2004; 11: 1705.